CLAIM #12170 · Bristol-Myers Squibb Company (BMY) · 2025Q2 earnings call · Jul 31, 2025 · due Dec 31, 2025
“We've continued to deliver strong growth with Camzyos. We're very pleased with performance as we've continued to increase new patient starts, and we've established a strong revenue base, and we expect that to continue from the expansion of our prescriber base, coupled with high persistency.”
Adam Lenkowsky · Chief Commercialization Officer
PENDING
graded after results covering Dec 31, 2025 are reported
Verify independently
SEC filings for BMY ↗ · Claim quote is verbatim from the 2025Q2 earnings call.